Our R&D facility in Mölndal is situated just south of Gothenburg, the second largest city in Sweden.

Over 2,700 people work at this site where research is primarily focused on diseases of the gastrointestinal and cardiovascular systems, with a long-standing record of success including Losec (Prilosec), Seloken and the latest addition to our GI range, Nexium.

Read more about this facility

Take a 360° tour of this facility.